How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

808 results for

Galantamine

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

81. Quantification of galantamine in human plasma by validated liquid chromatography-tandem mass spectrometry using glimepride as an internal standard: application to bioavailability studies in 32 healthy Korean subjects. Full Text available with Trip Pro

Quantification of galantamine in human plasma by validated liquid chromatography-tandem mass spectrometry using glimepride as an internal standard: application to bioavailability studies in 32 healthy Korean subjects. A simple, rapid and selective liquid chromatography method coupled with tandem mass spectrometry is developed and validated for the quantification of galantamine in human plasma using a commercially available compound, glimepride, as an internal standard (IS). Following simple one (...) -step liquid-liquid extraction by ethyl acetate, the analytes are separated using an isocratic mobile phase consisting of acetonitrile and 0.01M ammonium acetate (95/5, v/v) on a reverse-phase C18 column and analyzed by tandem mass spectrometry in the multiple reaction monitoring mode using the transitions of respective (M + H)(+) ions, m/z 288.22 → 213.20 and m/z 491.17 → 352.30 for the quantification of galantamine and IS, respectively. The standard calibration curves show good linearity within

2012 Journal of chromatographic science Controlled trial quality: uncertain

82. Galantamine versus donepezil in Chinese patients with Alzheimer's disease: results from a randomized, double-blind study. Full Text available with Trip Pro

Galantamine versus donepezil in Chinese patients with Alzheimer's disease: results from a randomized, double-blind study. Acetylcholinesterase inhibitors are considered standard of care for Alzheimer's disease in many countries. Galantamine is an acetylcholinesterase inhibitor that may also act via allosteric modulation of nicotinic acetylcholine receptors. Therefore, it may provide benefits compared with other acetylcholinesterase inhibitors. The present study compared galantamine (n = 116 (...) ) with donepezil (n = 117) in a double-blind trial at nine hospitals in China.After washout of any previous acetylcholinesterase inhibitors, subjects with mild to moderate Alzheimer's disease received galantamine or donepezil for 16 weeks.Alzheimer's Disease Assessment Scale - cognitive subscale (ADAS-cog/11) scores improved significantly from baseline in both treatment arms, with a significant difference in favor of galantamine on the "language" functional area (P = 0.035). Significantly more galantamine

2012 Neuropsychiatric disease and treatment Controlled trial quality: uncertain

83. Effects of memantine and galantamine on cognitive performance in aged rhesus macaques. (Abstract)

Effects of memantine and galantamine on cognitive performance in aged rhesus macaques. Current pharmacotherapies for Alzheimer's disease (AD) are focused on improving performance of daily activities, personal care, and management of problematic behaviors. Both memantine, a noncompetitive N-methyl-D-aspartate channel blocker and galantamine, a selective acetylcholinesterase inhibitor, are currently prescribed as symptomatic therapies for AD. However, drugs that progressed directly from testing (...) in rodent models to testing in AD patients in clinical trials failed to demonstrate consistent effects on cognitive symptoms. Considering the lack of nonhuman primate data on the effects of memantine and galantamine alone or in combination on cognitive dysfunction in aged nonhuman primates, the present study examined how closely data derived from aged nonhuman primates reflects data obtained in humans. Mild beneficial effects on aspects of cognitive performance in aged primates were found, in general

2012 Neurobiology of Aging

84. Effect of Galantamine on Short-term Abstinence

Effect of Galantamine on Short-term Abstinence Effect of Galantamine on Short-term Abstinence - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Effect of Galantamine on Short-term Abstinence (GAL-K (...) Institute (NCI) National Center for Research Resources (NCRR) National Institute on Drug Abuse (NIDA) Information provided by (Responsible Party): University of Pennsylvania Study Details Study Description Go to Brief Summary: This is a randomized, double-blind, placebo-controlled study to test whether a medication called galantamine (Brand Name: Razadyne) will help smokers quit and whether it reduces cognitive problems that smokers experience during a quit attempt. Condition or disease Intervention

2012 Clinical Trials

85. Effect of Galantamine on Smoking Abstinence

Effect of Galantamine on Smoking Abstinence Effect of Galantamine on Smoking Abstinence - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Effect of Galantamine on Smoking Abstinence The safety and scientific (...) Description Go to Brief Summary: This is a preliminary open-label study to determine whether a medication called galantamine (Brand Name: Razadyne) will help smokers quit and whether it reduces cognitive problems that smokers experience during a quit attempt. Condition or disease Intervention/treatment Phase Nicotine Addiction Drug: Galantamine ER Phase 2 Detailed Description: Galantamine, an FDA-approved treatment for Alzheimer's disease, is used to treat cognitive impairment by enhancing acetylcholine

2012 Clinical Trials

86. The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model. Full Text available with Trip Pro

The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model. Alzheimer’s disease (AD) is the most commonly occurring form of dementia. It is predominantly a disease of later life, affecting 5% of those over 65 in the UK.Review and update guidance to the NHS in England and Wales on the clinical effectiveness and cost-effectiveness (...) of donepezil, galantamine, rivastigmine [acetylcholinesterase inhibitors (AChEIs)] and memantine within their licensed indications for the treatment of AD, which was issued in November 2006 (amended September 2007 and August 2009).Electronic databases were searched for systematic reviews and/or metaanalyses, randomised controlled trials (RCTs) and ongoing research in November 2009 and updated in March 2010; this updated search revealed no new includable studies. The databases searched included The Cochrane

2012 Health technology assessment (Winchester, England)

87. The effect of galantamine on the blood pressure of the rat. Full Text available with Trip Pro

The effect of galantamine on the blood pressure of the rat. 4380412 1966 11 28 2018 11 13 0366-0826 26 2 1966 Feb British journal of pharmacology and chemotherapy Br J Pharmacol Chemother The effect of galantamine on the blood pressure of the rat. 295-301 Chrusciel M M Varagić V V eng Comparative Study Journal Article England Br J Pharmacol Chemother 0154627 0366-0826 0 Ganglionic Blockers 0 Parasympatholytics 0 Sympatholytics 0D3Q044KCA Galantamine IM Adrenalectomy Animals Blood Pressure drug (...) effects Female Galantamine pharmacology Ganglionic Blockers pharmacology Male Parasympatholytics pharmacology Rats Sympatholytics pharmacology 1966 2 1 1966 2 1 0 1 1966 2 1 0 0 ppublish 4380412 PMC1510659 J Physiol. 1948 Mar 15;107(2):162-4 16991795 Br J Pharmacol Chemother. 1964 Aug;23:34-42 14206267 J Physiol. 1953 Jan;119(1):43-57 13035716 Br J Pharmacol Chemother. 1964 Aug;23:80-9 14206271 Naunyn Schmiedebergs Arch Exp Pathol Pharmakol. 1957;230(5):448-56 13526758 J Pharmacol Exp Ther. 1962 Jan

1966 British journal of pharmacology and chemotherapy

88. Galantamine and behavior in Alzheimer disease: analysis of four trials. (Abstract)

Galantamine and behavior in Alzheimer disease: analysis of four trials. Many individuals with Alzheimer's disease (AD) experience behavioral and neuropsychiatric symptoms, which may cause caregiver distress and lead to the institutionalization of the patient. This analysis characterized behavioral symptoms and caregiver distress in trials of galantamine and their response to treatment.Data were pooled from four randomized, placebo-controlled clinical trials of galantamine in patients with mild (...) to moderate AD (three studies) or AD plus cerebrovascular disease (one study) (n = 2177). Behavior and associated caregiver distress were assessed in each study using the Neuropsychiatric Inventory (NPI) and NPI distress (NPI-D), respectively.After 5/6 months, but not after 3 months, NPI score was significantly improved with galantamine vs placebo (P = 0.013). The benefit was particularly pronounced in patients categorized as having advanced moderate AD. At 5/6 months, there was a numerical benefit

2011 Acta neurologica Scandinavica

89. Galantamine augmentation of long-acting injectable risperidone for cognitive impairments in chronic schizophrenia. (Abstract)

Galantamine augmentation of long-acting injectable risperidone for cognitive impairments in chronic schizophrenia. Galantamine, a reversible cholinesterase inhibitor with effects on nicotinic receptors, has shown mixed effects on cognitive impairments in patients with schizophrenia. Given these mixed results we examined whether galantamine compared to adjunctive placebo may improve cognitive functions in patients treated concomitantly with a long acting atypical antipsychotic.The parent study (...) was a 52-week double-blind, randomized study of treatment with long-acting injectable risperidone 25mg or 50mg every two weeks. Adjunctive galantamine or placebo treatment was administered from Month 6 to 12. Outcome measures were neurocognitive, psychopathology, social and quality of life functions. Patients were randomized to blinded galantamine up to 24mg/day or matching placebo tablets. All patients were maintained on their randomized long-acting injectable risperidone regimen for the duration

2011 Schizophrenia research Controlled trial quality: uncertain

90. Cessation versus continuation of galantamine treatment after 12 months of therapy in patients with Alzheimer's disease: a randomized, double blind, placebo controlled withdrawal trial. Full Text available with Trip Pro

Cessation versus continuation of galantamine treatment after 12 months of therapy in patients with Alzheimer's disease: a randomized, double blind, placebo controlled withdrawal trial. Galantamine improved symptoms in Alzheimer's disease (AD) patients after 5 to 6 months of treatment. To examine long-term outcomes, this study assessed if continuing of galantamine treatment beyond 12 months delayed further cognitive deterioration. It consisted of two phases: an open label (OL) phase (12 months (...) ), followed by a double blind, randomized, placebo controlled withdrawal phase (up to 24 months). Subjects with mild to moderate AD were included in the study and titrated up to 16 mg/day of galantamine. Subjects were eligible to enter the double blind phase if a cognitive decline of <4 points on AD Assessment Scale-cognitive subscale (ADAS-cog)/11 was recorded at the end of the OL phase. The differences between galantamine and placebo in time to dropout were estimated using the Cox proportional hazard

2011 Journal of Alzheimer's disease : JAD Controlled trial quality: predicted high

91. Long-term effects of galantamine treatment on brain functional activities as measured by PET in Alzheimer's disease patients. (Abstract)

Long-term effects of galantamine treatment on brain functional activities as measured by PET in Alzheimer's disease patients. The effects of galantamine (16 to 24 mg/day) treatment on brain functional activities (blood flow and glucose metabolism) were examined in 18 patients with mild Alzheimer's disease (AD) in relation to brain acetylcholinesterase (AChE) activity and nicotinic receptors and cognitive function. The study consisted of an initial double-blind phase of three months (short-term (...) patient in order to follow changes in cognition during the treatment period. Throughout the study, different cortical areas showed significant increases in rCBF after galantamine treatment. rCBF positively correlated with AChE activity, nicotinic receptors and cognition. In addition to these positive changes, an increase in rCMRglc in the frontal brain region and stabilization in other cortical areas was observed after 12 months galantamine treatment. This stabilization in rCMRglc was also correlated

2011 Journal of Alzheimer's disease : JAD Controlled trial quality: uncertain

92. Effects of galantamine in Alzheimer's disease: double-blind withdrawal studies evaluating sustained versus interrupted treatment. (Abstract)

Effects of galantamine in Alzheimer's disease: double-blind withdrawal studies evaluating sustained versus interrupted treatment. To evaluate the effects of galantamine withdrawal, and compare this with uninterrupted therapy, two 6-week double-blind withdrawal studies (Studies 1 and 2) were performed. These enrolled individuals who had completed one of two 3- or 5-month randomized clinical trials (parent trials) involving patients with mild to moderate Alzheimer's disease (AD). In Study 1 (GAL (...) -USA-11; n'723), patients continuously treated with galantamine 16 mg/day exhibited a mean (± standard error [SE]) improvement in 11-item cognitive subscale of the Alzheimer's Disease Assessment Scale score of 1.8 (± 0.46) points at Week 6 compared with the parent trial baseline, (p < 0.001 vs placebo; observed cases analysis). Over the same period, patients switched from galantamine to placebo and those who had received continuous placebo, exhibited mean (± SE) deteriorations of 0.7 (± 0.49

2011 Current Alzheimer research Controlled trial quality: uncertain

93. Galantamine improves sustained attention in chronic cocaine users. Full Text available with Trip Pro

Galantamine improves sustained attention in chronic cocaine users. Chronic cocaine users are known to have cognitive deficits that are predictive of poor treatment response. Whether these deficits improve with medications targeting specific cognitive functions has not been examined in previous studies. The goal of this study was to evaluate galantamine's efficacy on selected cognitive outcomes, including measures of sustained attention, response inhibition, and attentional bias in recently (...) abstinent cocaine users. Galantamine, a reversible and competitive inhibitor of acetylcholinesterase, is used clinically in the treatment of Alzheimer's dementia. In a randomized, double-blind, parallel-group study, 34 participants were randomized to galantamine (8 mg/day) or placebo treatment for 10 days. Cognitive and self-report mood measures were obtained at baseline and on Days 5 and 10 after the initiation of treatment. Galantamine treatment, compared to placebo, improved the reaction time, F(2

2011 Experimental and clinical psychopharmacology Controlled trial quality: uncertain

94. Development and in vivo evaluation of novel monolithic controlled release compositions of galantamine hydrobromide as against reservoir technology. (Abstract)

Development and in vivo evaluation of novel monolithic controlled release compositions of galantamine hydrobromide as against reservoir technology. The objective of this study is to develop and in vivo evaluation of novel monolithic matrix mini tablets approach to control the release of galantamine hydrobromide (GAH) in comparison with desired release profile to the Innovator formulation Razadyne(®) ER capsules. The direct compression method was employed for preparation of matrix mini tablets

2011 Pharmaceutical development and technology Controlled trial quality: uncertain

95. Long-term effects of galantamine on cognitive function in Alzheimer's disease: a large-scale international retrospective study. Full Text available with Trip Pro

Long-term effects of galantamine on cognitive function in Alzheimer's disease: a large-scale international retrospective study. In Alzheimer's disease (AD), it is important to consider long-term effects, not only in patients receiving treatment, but also in subjects in whom therapy has been discontinued. The present analysis evaluates the long-term effects of galantamine on cognitive function in AD in terms of Mini-Mental State Examination (MMSE) scores for up to 7 years, using both clinical (...) data and epidemiological modeling. Consideration is given not only to patients continuing to receive galantamine therapy, but also to those who stop this treatment. In a retrospective review of medical notes, re-contacted study investigators obtained data from 258 patients originally recruited into three previously described randomized clinical trials involving galantamine: two placebo-controlled trials in mild-to-moderate AD (of 3 and 6 months' duration, followed by open-label extensions

2011 Journal of Alzheimer's disease : JAD Controlled trial quality: uncertain

96. Galantamine Bioequivalence Study of Dr. Reddy's Under Fed Condition

Galantamine Bioequivalence Study of Dr. Reddy's Under Fed Condition Galantamine Bioequivalence Study of Dr. Reddy's Under Fed Condition - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Galantamine (...) Study Details Study Description Go to Brief Summary: Galantamine Hydrobromide Tablets, Bioequivalence study of Dr. Reddy's under Fed condition. Condition or disease Intervention/treatment Phase Fed Drug: Reminyl Phase 1 Detailed Description: Comparative, Randomized, Single-Dose, 2-way Crossover Bioavailability Study of Dr.Reddy's Laboratories, ltd. and Janssen Pharmaceutical Products, l.P. (Reminyl®)4 mg Galantamine HBr Tablets in Healthy Adult Male Volunteers under Fed Conditions Study Design Go

2011 Clinical Trials

97. Galantamine Bioequivalence Study of Dr. Reddy's Under Fasting Condition

Galantamine Bioequivalence Study of Dr. Reddy's Under Fasting Condition Galantamine Bioequivalence Study of Dr. Reddy's Under Fasting Condition - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Galantamine (...) Limited Study Details Study Description Go to Brief Summary: Galantamine Hydrobromide Tablets, Bioequivalence study of Dr. Reddy's under Fasting condition. Condition or disease Intervention/treatment Phase Fasting Drug: Reminyl Phase 1 Detailed Description: Comparative, Randomized, Single-Dose. 2-way Crossover Bioavailability Study of Dr.Reddy's laboratories, ltd. and Janssen Pharmaceutical Products. L.P. (Reminyte®)4 mg Galantamine HBr Tablets In Healthy Adult Male Volunteers under fasting Conditions

2011 Clinical Trials

98. Cognitive Rehabilitation and Galantamine for Post Stroke Cognitive Impairment

Cognitive Rehabilitation and Galantamine for Post Stroke Cognitive Impairment Cognitive Rehabilitation and Galantamine for Post Stroke Cognitive Impairment - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more (...) . Cognitive Rehabilitation and Galantamine for Post Stroke Cognitive Impairment (COGICRehab) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01508494 Recruitment Status : Unknown Verified April 2015 by Institut National de la Santé Et de la Recherche Médicale, France. Recruitment status was: Recruiting

2011 Clinical Trials

99. Evaluation of Efficacy and Safety of Galantamine in Patients With Dementia of Alzheimer's Type Who Failed to Benefit From Donepezil

Evaluation of Efficacy and Safety of Galantamine in Patients With Dementia of Alzheimer's Type Who Failed to Benefit From Donepezil Evaluation of Efficacy and Safety of Galantamine in Patients With Dementia of Alzheimer's Type Who Failed to Benefit From Donepezil - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have (...) reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Evaluation of Efficacy and Safety of Galantamine in Patients With Dementia of Alzheimer's Type Who Failed to Benefit From Donepezil The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01478633

2011 Clinical Trials

100. Galantamine Effects on Nicotine Responses in Smokers

Galantamine Effects on Nicotine Responses in Smokers Galantamine Effects on Nicotine Responses in Smokers - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Galantamine Effects on Nicotine Responses in Smokers (...) University Study Details Study Description Go to Brief Summary: This will be a 2-4 week double-blind, placebo-controlled study. Twenty four male and female smokers will first have two 4-day treatment periods, in which they will be randomized to galantamine (8 mg/day) or placebo. These treatment periods will be separated by a 3 to 14 day washout period. During the first 3-days of each treatment period, smokers will have daily clinic visits, where they will receive study medications and any adverse effects

2011 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>